Overview
Beginning at the earliest stages of development, innovative pharmaceuticals, biologics, and medical devices are subject to a web of different legal and regulatory requirements. Our Industry Research and Clinical Trials team regularly engages in the intricate process of helping clients shepherd new products from early-stage development through clinical development and on to commercial viability.
Our clients represent all sectors of the life sciences research industry, from pharmaceutical, biotech, medical device, and other technology companies to a broad range of contract research organizations and other research services providers.
Where Innovation Meets Industry
Much of our work revolves around relationships between industry sponsors and the many partners on which they rely to operationalize their clinical development programs, where nuanced interpretation of regulatory issues is a business necessity. Our clients trust us to arrange their transactions, negotiate their service agreements and other contracts, and facilitate the efficient implementation of their protocols. We are known for our ability to manage the relationships between and among research-industry players, advising them on critical business issues and resolving areas of potential conflict based on industry knowledge acquired through our decades of work in the clinical research industry.
Focus on Research
Our lawyers think about research support full-time. Most of us have worked on the ground in the clinical research space—as in-house counsel at life sciences companies, for research services providers, and serving on institutional review boards—so we understand the operational implications of our advice. We know best practices because we’ve lived them, and our clients rely on that experience to put in place policies and procedures that keep their research compliance house in order while allowing them to remain bold in their pursuit of important breakthroughs.
Read less
Focus Areas
Trending Issues
Experience
- Supported the vendor and research institution contracting needs of a pharmaceutical manufacturer client that initiated a global Phase III clinical trial of more than 50 sites in 12 countries in coordination with the contract research organization and an international network of local counsel.
- Built research compliance programs and conducted gap assessments of existing compliance programs, providing day-to-day advice and counseling on research compliance matters, and supplying guidance on research billing compliance and financial conflict-of-interest matters.
- Represented numerous pharmaceutical and medical device companies in the drafting and negotiation of clinical trial agreements and investigator-initiated study agreements for trials conducted in the United States and abroad. We also interfaced with research organizations, government entities, clinical research organizations, and third-party suppliers on behalf of those pharmaceutical and medical device companies on a broad range of issues throughout the life cycle of their clinical trials.
- Counseled sponsors on clinical trial issues involving novel technologies involving wearable devices and decentralized clinical trials.
- Served as transactional and regulatory counsel to multiple clinical research site companies in connection with a strategic partnership with, and growth investment by, strategic and private equity firms.
- Created clinical trial research corporate compliance programs for various manufacturers, clinical research organizations, and site management organizations, including compliance with Good Clinical Practices, human subject protection compliance procedures, and procedures regarding investigator-initiated research. The programs also addressed relationships with research sites, researchers, vendors, professional organizations, independent foundations, and other participants in the clinical research process.
- Advised a U.S.-based digital health startup company about regulatory, privacy, data protection, contracting, and fraud and abuse laws in preparation for the launch of its digital health platform. Epstein Becker Green assisted the company in establishing and implementing a research pilot, developing a compliant platform, contracting with providers, implementing a patient engagement strategy, and building trust among other stakeholders.
Contacts
Board of Directors / Member of the Firm
Member of the Firm
Member of the Firm
Media
Events
Past Events
- July 28, 2022
Insights
Insights
- Media CoverageJames Boiani Quoted in “FDA Moving Quickly on LDT Rulemaking as 2024 Elections, 2027 User Fee Renewal Loom” ...2 minute read
- Media CoverageRobert Hearn Quoted in “Surveying Laboratory Tests from a Health IT Perspective”3 minute read
- Firm Announcements
Jessika Tuazon Named to the 2023 Southern California Rising Stars List
6 minute read - PublicationsBradley Merrill Thompson Quoted in “FDA’s Human Factors Draft Draws Fire for Introduction of ‘Critical Task’ ...2 minute read
- Media CoverageBradley Merrill Thompson Quoted in “FDA Outlines Plan for Digital Health Technologies for Clinical Trials”4 minute read
- Media CoverageJames Boiani Quoted in “Congress Has a Chance to Close the FDA’s Theranos Loophole”3 minute read
- Firm AnnouncementsEpstein Becker Green Announces 2023 PromotionsOctober 28, 20225 minute read
- Firm Announcements
Epstein Becker Green’s Amy Dow Honored in Crain’s 2022 Notable Women in Law
2 minute read - PublicationsOHRP Draft Guidance on the Use of Single IRBs: Reminder to Comment by August 308 minute read
- Firm Announcements
Jessika Tuazon Named to the 2022 Southern California Rising Stars List
5 minute read - Media CoverageBradley Merrill Thompson Quoted in “Clinical Decision Support Guidance Tops FDA’s Agenda for 2022”2 minute read
- Media CoverageBradley Merrill Thompson Quoted in “FDA's 2022 A-List Guidance Plan Hits on Software, Post-Pandemic Future” ...4 minute read